

Financial Tear Sheet

Corporate Profile

ContraFect Corporation is a biotechnology company focused on discovering and developing therapeutic protein and antibody products for life-threatening, drug-resistant infectious diseases, particularly those treated in hospital settings. Due to drug-resistant and newly emerging pathogens, hospital acquired infections are currently the fourth leading cause of death in the United States, following heart disease, cancer and stroke. We intend to address drug-resistant infections using our therapeutic product candidates from our lysin and monoclonal antibody platforms to target conserved regions of either bacteria or viruses (regions that are not prone to mutation).

Primary IR Contact


Barbara Ryan
 Partner
 Claremont Partners
Phone: (203) 274-2825
E-mail:
bryan@clermontpartners.com

Stock Information

CFRXZ (Warrant to purchase common stock)

Exchange	NASDAQ CM (US Dollar)
Price	\$1.80
Change (%)	0.00 (0.00%)
Volume	0
52 Week Low	\$0.80
Market Cap	\$132,651,603
Rolling EPS	-0.42
PE Ratio	0
Shares Outstanding	73,658,506

Data as of 05/22/18 3:59 p.m. ET



Recent Press Releases & Events

05/10/18 - 7:00 a.m.

[ContraFect Announces First Quarter 2018 Financial Results](#)

04/11/18 - 9:00 a.m.

[ContraFect to Present CF-301 Data at the 28th European Congress of Clinical Microbiology and Infectious Diseases \(ECCMID\)](#)

03/15/18 - 7:00 a.m.

[ContraFect Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update](#)

There are currently no events scheduled.

SEC Filings

Filing Date	Form
05/10/18	10-Q
05/10/18	S-8
05/10/18	8-K
05/10/18	4

Management

Julia P. Gregory	Chief Executive Officer
Cara Cassino	Chief Medical Officer
Dr. Michael Wittekind, Ph.D.	Chief Scientific Officer and Sr. Vice President, Research
Daniel Couto	Senior Vice President, Manufacturing & Facilities Operations
Josh Muntner	Sr. VP, Business Development
Nancy Dong	Vice President, Controller
Michael Messinger, CPA	Vice President, Finance
Natalie Bogdanos	General Counsel and Corporate Secretary

Data provided by Nasdaq. Minimum 15 minutes delayed.